Target intelligence / Profile preview

Gamma-crystallin N (CRYGN)

Target
CRYGN
Molecular classification
Structural protein, Crystallin family
01

Overview

Gamma-crystallin N (CRYGN) is a member of the crystallin protein family and is one of the main structural proteins found in the vertebrate eye lens, where it plays a key role in preserving transparency and maintaining the refractive index. CRYGN displays both beta and gamma crystallin protein motifs, which is unique among crystallins. Its expression is tightly regulated after early development and genetic or age-related changes in CRYGN are implicated in the formation of cataracts due to protein degradation or mutation. CRYGN is considered a structural, rather than therapeutic, target and is not classified as an enzyme, receptor, transporter, or drug target, but is essential for the physical structure and function of the eye lens[1][2][3][5].

Other names
Gamma-N-crystallingamma-crystallin Ngamma-N-crystallingammaN-crystallinCRYGN
02

Biological functions

Maintenance of lens transparencyStructural integrity of the eye lens
03

Disease associations

Cataract (due to age-related degradation or genetic mutation)Other (no robust link to other disease classes)

Beyond the preview

Go deeper on Gamma-crystallin N (CRYGN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gamma-crystallin N (CRYGN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call